ProfileGDS5678 / 1423735_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 84% 86% 85% 83% 83% 82% 84% 82% 84% 82% 86% 86% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3730185
GSM967853U87-EV human glioblastoma xenograft - Control 26.3352184
GSM967854U87-EV human glioblastoma xenograft - Control 36.484886
GSM967855U87-EV human glioblastoma xenograft - Control 46.5488385
GSM967856U87-EV human glioblastoma xenograft - Control 56.1555883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8573183
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8199982
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1431884
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8738182
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2679184
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9614482
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5074986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4586186
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2372884